Hudson Bay Capital Management
CLRB icon

Hudson Bay Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Hudson Bay Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,000
Closed -$375K – 897
2024
Q2 		$375K Hold
5,000
– – ﹤0.01% 650
2024
Q1 		$597K Buy
+5,000
New +$542K ﹤0.01% 573

Other funds holding CLRB

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hudson Bay Capital Management's CLRB Position: Q3 2024 in Review

Hudson Bay Capital Management sold out of Cellectar Biosciences (CLRB) in Q3 2024, closing a stake of 5,000 shares — an estimated $375K sold.

Hudson Bay Capital Management first reported a position in CLRB in Q1 2024 and held it in 2 quarters. The position peaked at $597K in Q1 2024. 35 funds tracked by Wall St. Rank hold CLRB as of Q3 2024.

  • Hudson Bay Capital Management reported no remaining Cellectar Biosciences position as of Q3 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 5,000 Cellectar Biosciences shares in Q3 2024, an estimated $375K.
  • Hudson Bay Capital Management first reported a position in Cellectar Biosciences in Q1 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Cellectar Biosciences position peaked at $597K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2024.

Based on Hudson Bay Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.